Depression Moderate, Depression Severe, Survey Methodology
Showing 1 - 25 of >10,000
Depression Mild, Depression Moderate, Depression Severe Trial (Integrated care)
Not yet recruiting
- Depression Mild
- +2 more
- Integrated care
- (no location specified)
Mar 27, 2023
Moderate Depression, Severe Depressive Episode Without Psychotic Symptoms, Recurrent Depressive Disorder, Current Episode
Recruiting
- Moderate Depression
- +3 more
- Transcranial Pulsed Electromagnetic Fields (T-PEMF) delivered via a headband
- No treatment delivered via headband
-
Frederiksberg, Capital Region, DenmarkPsychiatric Center Copenhagen
Aug 15, 2023
Moderate Depression, MDD, Severe Depression Trial (4 session rTMS, 6 session rTMS, 8 session rTMS)
Not yet recruiting
- Moderate Depression
- +2 more
- 4 session rTMS
- +4 more
- (no location specified)
Apr 24, 2023
Moderate Depression, MDD, Severe Depression Trial (active rTMS: 20min inter-session interval, active rTMS: 50min inter-session
Not yet recruiting
- Moderate Depression
- +2 more
- active rTMS: 20min inter-session interval
- +3 more
- (no location specified)
Jul 14, 2023
Treatment Resistant Depression Trial in Saint Louis (Ketamine Infusion plus RO DBT)
Recruiting
- Treatment Resistant Depression
- Ketamine Infusion plus RO DBT
-
Saint Louis, MissouriWashington University School of Medicine
Nov 21, 2023
Exercise Recovery From Persistent Depression: A Thematic
Not yet recruiting
- Major Depressive Disorder
- +2 more
-
Nottingham, Nottinghamshire, United KingdomNottinghamshire Healthcare NHS Foundation Trust
Sep 13, 2022
MDD Trial in Islamabad (Sertraline, Escitalopram)
Completed
- Major Depressive Disorder
-
Islamabad, PakistanKRL Hospital
Jul 14, 2023
Moderate Depression, MDD, Severe Depression Trial in Beijing (4 session rTMS, 6 session rTMS, 8 session rTMS)
Not yet recruiting
- Moderate Depression
- +2 more
- 4 session rTMS
- +4 more
-
Beijing, Beijing, ChinaWuhan Mental Health Center
Oct 29, 2023
Depression Trial in Guangzhou (Control group: Fluoxetine and Placebo, Experimental group: Fluoxetine and ATP, Experimental
Recruiting
- Depression
- Control group: Fluoxetine and Placebo
- +2 more
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Jun 23, 2022
MDD, Traumatic Brain Injury Trial in Boston (Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control)
Active, not recruiting
- Major Depressive Disorder
- Traumatic Brain Injury
- Cognitive Behavioral Therapy for individuals with TBI
- Waitlist Control
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2022
Moderate or Severe Major Depressive Disorder Requiring Urgent
Not yet recruiting
- Depressive Disorder, Major
-
Manchester, United KingdomGreater Manchester Mental Health NHSFT
Jan 31, 2023
Mental Health and Cognitive Disorders on Quality of Life in
Not yet recruiting
- COVID-19 Post-Intensive Care Syndrome
- Montreal cognitive assessment scale (MOCA)
- (no location specified)
Apr 30, 2023
MDD, MDD, Recurrent Episode, Severe, MDD, Recurrent, Moderate Trial in Minnetonka (NeuroStar TMS)
Completed
- Major Depressive Disorder
- +2 more
- NeuroStar TMS
-
Minnetonka, MinnesotaSonder Behavioral Health and Wellness
Nov 3, 2023
COVID-19, Stress Disorders, Post-Traumatic Trial in Chambéry (Revised Impact of Event Scale, Hospital Anxiety and Depression
Completed
- COVID-19
- Stress Disorders, Post-Traumatic
- Revised Impact of Event Scale
- +5 more
-
Chambéry, FranceCH Metropole Savoie
Jun 16, 2022
Depression, Unipolar Trial in Essen (Whole-body hyperthermia + standard medical care, Standard medical care)
Recruiting
- Depression, Unipolar
- Whole-body hyperthermia + standard medical care
- Standard medical care
-
Essen, GermanyDepartment of Psychiatry, Psychotherapy and Addiciton Medicine,
Nov 12, 2021
Explore the Role of Gut Flora in Depression
Recruiting
- Depression
- +8 more
- No Intervention
-
Ventura, CaliforniaProgenaBiome
Sep 2, 2021
Major Depression Trial in United States (SAGE-217, Placebo)
Associated With Suicidality in Inpatients With Symptoms of
Recruiting
- Depression
- +5 more
-
Berlin-Mitte, GermanyCharité
May 19, 2021
Postpartum Depression Trial in United States (Placebo, SAGE-547 90 µg/kg/h)
Completed
- Postpartum Depression
- Placebo
- SAGE-547 90 μg/kg/h
-
Chandler, Arizona
- +31 more
Jan 20, 2022
Acute Pain, Burns, Adverse Drug Event Trial (Oliceridine, Historical opioid use)
Not yet recruiting
- Acute Pain
- +4 more
- Oliceridine
- Historical opioid use
- (no location specified)
Jul 25, 2022
MRS and Medication Response: A Pilot Study
Terminated
- Major Depressive Disorder
- +5 more
-
Stanford, CaliforniaStanford University Psychiatry and Biobehavioral Sciences
Aug 12, 2021
Shortened Depression Assessment Study
Completed
- Depression
-
Toronto, Ontario, CanadaUniversity of Toronto
Nov 5, 2021
Phantom Limb Pain (PLP) Trial in Charlotte (virtual reality therapy, matched control group)
Not yet recruiting
- Phantom Limb Pain (PLP)
- virtual reality therapy
- matched control group
-
Charlotte, North CarolinaOrthoCarolina Hand Center
Oct 4, 2023